Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback